Author

Anna Backmark

AstraZeneca (Sweden)ORCID 0000-0001-8973-0488Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexander MörseburgiD· 1 shared Audrey MelviniD· 1 shared Benjamin P. Readhead· 1 shared Björn Magnusson· 1 shared Carly MeadoriD· 1 shared Christine BeckeriD· 1 shared Daniel G. FosteriD· 1 shared Esther Guiu‐JuradoiD· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Alexander MörseburgORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The common H202D variant in GDF-15 does not affect its bioactivity but can significantly interfere with measurement of its circulating levels

Yanislava Karusheva, Matthew Ratcliff, Alexander Mörseburg, Peter Barker, Audrey Melvin, Naveed A. Sattar, Keith Burling, Anna Backmark, Robert G. Roth, Lutz Jermutus, Esther Guiu‐Jurado, Matthias Blüher, Paul I. Welsh, Marko Hyvönen, Stephen O’Rahilly

The study shows that the H202D variant in GDF-15 does not affect its bioactivity but causes underreporting in R&D immunoassays, with correction equations provided.

The Journal of Applied Laboratory Medicine · Jul 7, 2022Peer-reviewedGenetic & Genomic Medicine

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis

Farida Ahangari, Christine Becker, Daniel G. Foster, Maurizio Chioccioli, Meghan Nelson, K.M. Beke, Xing Wang, Benjamin P. Readhead, Carly Meador, Kelly A. Correll, Loukia N. Lili, Helen M. Roybal, Kadi-Ann Rose, Shuizi Ding, Thomas Bärnthaler, , Gregory Paul Downey

This study identifies saracatinib as a potential anti-fibrotic drug effective in multiple models of pulmonary fibrosis, showing equal or superior efficacy compared to existing treatments.

bioRxiv · Jan 4, 2022 · PreprintSystems Biology